Gene Editing And New Therapies Will Transform Global Healthcare

Published
18 Jul 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$485.81
18.5% undervalued intrinsic discount
14 Aug
US$395.92
Loading
1Y
-16.0%
7D
2.7%

Author's Valuation

US$485.8

18.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 3.34%

Shared on30 Apr 25
Fair value Decreased 0.25%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25
Fair value Increased 0.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 0.034%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.85%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.085%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.014%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 0.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.